NCT06533059
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatmentAlterome Therapeutics, Inc.
~110 participants
Updated 2026-07-15 on ClinicalTrials.gov
What's tested:ALTA2618
At a glance
Recruiting sites
0 of 31 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adverse Events
Measured over Up to 39 months
+1 more outcome measured
Conditions
Where it's being run
31 sites across 18 statesUnited Kingdom5
Spain4
Texas3
Massachusetts2
France2
Japan2
South Korea2
California1
Study leadership
- Study Medical Director · STUDY_DIRECTOR · Alterome Therapeutics
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Histologically confirmed diagnosis of a solid tumor malignancy harboring AKT1 E17K mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic test.
Unresectable or metastatic disease
Progressed on, intolerant to, or declined prior standard-of-care therapy (including targeted therapy, if applicable) appropriate to tumor type and stage
Evaluable or measurable disease per RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate organ function.
Exclusion
Prior treatment with PI3K and/or mTOR inhibitors
Patients known to have KRAS, NRAS, HRAS, or BRAF genomic alterations in their tumor
Known condition that prohibits ability to swallow or absorb an oral medication
What this trial measures
- Adverse EventsUp to 39 months
Number of participants that experience treatment-emergent adverse events (TEAEs).
- Dose Limiting Toxicities21 days
Number of participants with Dose Limiting Toxicities (DLTs).